AZD-3759
CAS No. 1626387-80-1
AZD-3759 ( AZD-3759 )
Catalog No. M12405 CAS No. 1626387-80-1
A potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
10MG | 35 | In Stock |
|
25MG | 56 | In Stock |
|
50MG | 80 | In Stock |
|
100MG | 125 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAZD-3759
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR).
-
DescriptionA potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR); fully penetrate the blood-brain barrier (BBB), with equal free concentrations in the blood, cerebrospinal fluid, and brain tissue; causes tumor regression in subcutaneous xenograft, leptomeningeal metastasis (LM), and brain metastasis (BM) lung cancer models and prevents the development of BM in nude mice.Lung Cancer Phase 1 Clinical
-
SynonymsAZD-3759
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR(exon19Del);EGFR(L858R);EGFR(WT)
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number1626387-80-1
-
Formula Weight459.90
-
Molecular FormulaC22H23ClFN5O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(N1[C@H](C)CN(C)CC1)OC2=CC3=C(NC4=CC=CC(Cl)=C4F)N=CN=C3C=C2OC
-
Chemical Name1-Piperazinecarboxylic acid, 2,4-dimethyl-, 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl ester, (2R)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zeng Q, et al. J Med Chem. 2015 Oct 22;58(20):8200-15.
2. Yang Z, et al. Sci Transl Med. 2016 Dec 7;8(368):368ra172.
3. Tan CS, et al. Lung Cancer. 2016 Mar;93:59-68.
2. Yang Z, et al. Sci Transl Med. 2016 Dec 7;8(368):368ra172.
3. Tan CS, et al. Lung Cancer. 2016 Mar;93:59-68.
molnova catalog
related products
-
Poziotinib hydrochlo...
Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.?It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.?
-
Cetuximab (anti-EGFR...
Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
-
Nimotuzumab
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).